Yes, ADHD stimulant medications can modestly slow a child’s growth — but the effect is smaller than most parents fear. Research consistently shows that stimulants like methylphenidate and amphetamines reduce height growth by approximately 1 cm per year during the first two to three years of treatment, and the impact on final adult height appears to land somewhere between negligible and roughly one inch. For a parent watching their eight-year-old fall behind on the growth chart after starting medication, that distinction matters enormously.
But so does context: a 2020 systematic review published in Neuroscience & Biobehavioral Reviews found that the largest cohort study on the subject reported children with ADHD were 1.29 cm shorter on average than their peers whether or not they ever took medication, suggesting that ADHD itself — not just the pills — may play a role in height differences. This article unpacks what the clinical evidence actually says about stimulant medications and childhood growth, including the specific numbers from major studies, the mechanism behind growth suppression, what happens when children stop taking medication, and why a May 2025 study has renewed concerns about long-term safety data. If your child takes or may soon take ADHD medication, understanding these tradeoffs is essential for making an informed decision alongside your pediatrician.
Table of Contents
- How Much Do ADHD Stimulant Medications Affect a Child’s Growth?
- What Happens to Final Adult Height After Years of ADHD Medication?
- The Growth Rebound Effect — Do Children Catch Up After Stopping Medication?
- Why Do Stimulants Suppress Growth, and What Can Parents Do About It?
- Long-Term Safety Concerns and What a 2025 Study Revealed
- When Growth Concerns Should Change the Treatment Plan
- The Bigger Picture for Brain Health and Development
- Conclusion
- Frequently Asked Questions
How Much Do ADHD Stimulant Medications Affect a Child’s Growth?
The numbers vary depending on which study you read, but a consistent picture has emerged. A 2020 systematic review and meta-analysis found that methylphenidate treatment slowed height gain by approximately 1.39 cm and weight gain by 1.96 kg for a 10-year-old boy over a two-year period. At 36 months, newly medicated children showed a decreased growth of 2 cm in height compared to unmedicated peers. The well-known MTA Study — the Multimodal Treatment Study of adhd, one of the largest and most cited trials in ADHD research — found a growth deficit difference of –1.44 cm between medication-managed and behavior-managed groups over the study period. These are not dramatic numbers, but they are real and measurable. To put this in perspective, consider a 10-year-old boy who is projected to reach 5 feet 10 inches as an adult.
A 1 to 2 cm reduction in height means he might end up closer to 5 feet 9.5 inches — a difference that most people would never notice. However, that average masks a wide range of individual experiences. Some children show virtually no growth impact, while others on higher doses for longer durations may see more significant effects. The MTA follow-up data, for instance, reported that the most consistent medication users experienced a mean adult height deficit of up to 4.7 cm — nearly two inches — which is far more clinically noticeable. The weight effects tend to appear first and recover faster. Most studies report that the most prominent impact on weight occurs within the first 12 months of treatment, while height effects become most apparent within the first 24 to 30 months. This timeline matters for parents and clinicians monitoring growth trajectories.
What Happens to Final Adult Height After Years of ADHD Medication?
The question parents really want answered is not whether their child will grow slower during treatment, but whether their child will end up shorter as an adult. The evidence here is genuinely mixed. For children who continued medication consistently through childhood and adolescence, expected adult height was reduced by approximately 2.36 to 2.55 cm — roughly one inch. That figure comes from pooled data across multiple studies, and it represents a statistically significant but modest clinical effect. However, one critical finding complicates the picture.
The largest cohort study on this topic reported an overall adult height deficit of 1.29 cm in subjects who received stimulant medications — but children with ADHD who never took medication were also 1.29 cm shorter on average than their non-ADHD peers. This raises an important question that researchers have not fully resolved: is the height difference caused by the medication, by ADHD itself, or by some combination of both? Some researchers hypothesize that the neurobiological differences underlying ADHD may independently affect growth hormone regulation or developmental timing. There is also a notable sex difference. Women who took ADHD medication for more than a year during childhood were only about 0.6 cm shorter on average than controls — a difference so small it falls within normal measurement variation. This suggests that the growth impact may not be uniform across all children, and that factors like sex, dosage, duration of treatment, and individual biology all play a role. If your child’s doctor quotes you a single number for expected height loss, understand that it is an average drawn from a wide distribution of outcomes.
The Growth Rebound Effect — Do Children Catch Up After Stopping Medication?
One of the more reassuring findings in this research is the growth rebound phenomenon. Most studies conclude that discontinuing stimulant treatment results in catch-up growth that partially or fully compensates for height lost during treatment. This is particularly relevant for families who use medication during the school year and take breaks during summers, or who plan to discontinue medication in the teen years once executive function skills have matured. Consider a child who takes methylphenidate from ages 7 to 12 and falls about 2 cm behind projected height during that period.
If that child stops medication at 12, the growth rebound may allow them to recover much or all of that deficit before reaching adult height — particularly since the pubertal growth spurt provides a natural window for accelerated growth. The research on women who took medication for more than a year showing only a 0.6 cm adult height difference may partly reflect this rebound effect. That said, the rebound is not guaranteed to be complete, and it appears to depend on how long and how consistently the child was medicated. Children in the MTA study who took stimulants most consistently through adolescence showed the largest adult height deficits, up to 4.7 cm, suggesting that continuous long-term use may outpace the body’s ability to fully catch up. Families considering medication breaks — sometimes called “drug holidays” — should discuss this strategy with their prescribing physician, weighing the potential growth benefit against the academic and behavioral costs of unmanaged ADHD symptoms.
Why Do Stimulants Suppress Growth, and What Can Parents Do About It?
The primary mechanism behind stimulant-related growth suppression is appetite suppression. Methylphenidate and amphetamine-based medications reduce hunger, which leads to lower caloric intake — and growing children need calories. When a child consistently eats less than their body requires for normal development, growth slows. There is also evidence suggesting possible suppression of growth hormone during active treatment, though this mechanism is less well established than the nutritional pathway. Practically, this means that some of the growth effect is modifiable.
Parents who work actively to ensure adequate nutrition — calorie-dense breakfasts before the medication kicks in, substantial after-school snacks as the medication wears off, and protein-rich evening meals — may be able to mitigate some of the growth impact. Some clinicians recommend weekend and summer medication breaks specifically to allow appetite and weight recovery, though the evidence on whether drug holidays meaningfully protect final adult height is not definitive. The dose-dependent nature of the effect also matters. Greater height and weight attenuation has been observed in children who took medication more consistently and at higher doses. This creates a practical tradeoff: the dose that most effectively manages ADHD symptoms may also carry the greatest growth impact. Working with a clinician to find the lowest effective dose — and reassessing that dose regularly as the child grows — is one of the most concrete steps families can take.
Long-Term Safety Concerns and What a 2025 Study Revealed
A May 2025 study raised a concern that has been quietly acknowledged in pediatric psychiatry for years: the average duration of ADHD medication for children and adolescents is more than three years, yet reliable controlled safety data is available for only about one year of follow-up. This gap means that much of what clinicians tell parents about long-term growth effects is extrapolated from shorter studies or drawn from observational data, which cannot control for all confounding variables. This does not mean the medications are dangerous. It means the evidence base is less robust than parents might assume when a doctor confidently prescribes a medication their child may take for years.
Randomized controlled trials — the gold standard — are difficult to run over many years, particularly in children, for both ethical and practical reasons. The result is that families and clinicians are making long-term decisions based on a patchwork of one-year trials, observational cohorts, and clinical experience. For parents, the takeaway is not to panic but to stay engaged. Regular monitoring of height and weight on standardized growth charts is standard practice, and any child who drops significantly on their growth curve warrants a conversation about dose adjustment, medication breaks, or alternative treatments. CHADD — Children and Adults with ADHD — states that while some slowing of growth can occur, it is generally modest, typically 1 to 2 cm below projected height in a small number of children, and “likely not” clinically significant for most.
When Growth Concerns Should Change the Treatment Plan
Not every child on stimulant medication will experience noticeable growth effects, but some will. A child who was tracking along the 50th percentile for height and drops to the 25th percentile after a year on medication deserves closer scrutiny. Similarly, a child who shows significant weight loss or persistent appetite suppression that does not improve with dietary strategies may benefit from switching to a non-stimulant medication like atomoxetine or guanfacine, which have different side-effect profiles and generally less impact on appetite and growth.
The decision to modify treatment should never be made on growth data alone. A child whose ADHD is well-managed on stimulant medication and who has dropped only modestly on the growth curve is in a very different situation from a child who is struggling both behaviorally and physically. These are conversations best had with a pediatrician or child psychiatrist who can weigh the full picture — not decisions to make based on a single study or a frightening headline.
The Bigger Picture for Brain Health and Development
ADHD medications remain one of the most effective treatments in all of psychiatry, with response rates above 70 percent for stimulants. The growth question is real and worth taking seriously, but it exists within a larger context: untreated ADHD carries its own developmental risks, including academic failure, social difficulties, increased injury rates, and long-term mental health consequences that can extend well into adulthood.
For a brain health perspective, the cognitive and emotional benefits of well-managed ADHD often outweigh a centimeter or two of height. As research continues — and as longer-term safety data becomes available — clinicians will be better equipped to personalize treatment recommendations based on individual risk factors. In the meantime, the evidence supports a watchful, informed approach: use the lowest effective dose, monitor growth regularly, consider medication breaks when appropriate, and keep the conversation open between families and their medical team.
Conclusion
ADHD stimulant medications do appear to slow growth during active treatment, with most studies converging on a reduction of roughly 1 cm per year in the first two to three years. The effect on final adult height is more uncertain, ranging from negligible to approximately one inch depending on the study, the duration of use, and individual factors. A growth rebound after stopping medication can recover some or all of the lost height, but the most consistent long-term users may see a persistent deficit.
The 2025 finding that long-term safety data remains limited should motivate ongoing vigilance, not alarm. For parents navigating this decision, the key is informed monitoring rather than avoidance. Work with your child’s physician to track growth carefully, optimize nutrition, use the lowest effective dose, and revisit the treatment plan at regular intervals. The modest growth trade-off may be well worth the cognitive, academic, and emotional benefits of effective ADHD management — but that calculus is personal, and it deserves a thoughtful, individualized conversation with your child’s care team.
Frequently Asked Questions
Will my child definitely be shorter as an adult if they take ADHD medication?
Not necessarily. While studies show a modest average reduction in adult height of roughly 1 to 2.5 cm, many children experience minimal or no lasting effect. The largest cohort study found that children with ADHD were shorter on average regardless of whether they took medication, and growth rebound after discontinuation can recover lost height.
Are non-stimulant ADHD medications safer for growth?
Non-stimulant options like atomoxetine and guanfacine generally have less impact on appetite and may carry a smaller growth risk, though they are also typically less effective at managing core ADHD symptoms. Discuss the tradeoffs with your child’s prescribing clinician.
Do medication breaks or “drug holidays” help protect growth?
They may. Allowing periods without medication — weekends, summers, or planned breaks — can restore appetite and allow some catch-up growth. However, the evidence on whether drug holidays meaningfully protect final adult height is not conclusive, and unmanaged ADHD symptoms during breaks carry their own costs.
At what point should I worry about my child’s growth on ADHD medication?
If your child drops significantly on their growth percentile curve — for example, from the 50th to the 25th percentile — or experiences persistent weight loss and poor appetite that does not improve with dietary strategies, raise the issue with your pediatrician. Routine growth monitoring at every visit is standard practice for children on stimulants.
Does the type of stimulant matter — methylphenidate versus amphetamine?
Both classes of stimulant medications have been associated with growth effects. The impact appears to be dose-dependent across both types rather than specific to one class, though individual children may respond differently to each.
How long does it take for growth to catch up after stopping medication?
The growth rebound typically begins relatively quickly after discontinuation, but how long it takes to fully catch up depends on how long the child was medicated and at what dose. Children who stop medication before or during puberty may have a better window for catch-up growth due to the natural pubertal growth spurt.
